Skin disease caused by bacterial infection

Summary

Skin disease caused by bacterial infection (MONDO:0024295) is a disease (an umbrella term covering 17 Mondo subtypes) and 5 clinical trials. Top therapeutic interventions include linezolid, omadacycline, and delafloxacin. A subtype of bacterial infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Umbrella term: 17 Mondo subtypes
• Clinical trials: 5

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	skin disease caused by bacterial infection
Mondo ID	MONDO:0024295
MeSH	D017192
Is cancer (heuristic)	no

Also known as: Bacteria caused skin disease caused by infection · Bacteria skin disease caused by infection · bacterial skin disease · bacterial skin diseases · disease, bacterial skin · diseases, bacterial skin · skin disease, bacterial

Disease family

This is a subtype of bacterial infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › skin disease caused by bacterial infection

Related subtypes (51): primary bacterial infectious disease, commensal bacterial infectious disease, opportunistic bacterial infectious disease, chorioamnionitis, Clostridium difficile colitis, bacterial gastritis, bacterial arthritis, bacterial pneumonia, Whipple disease, Aeromonas hydrophila infectious disease, Pectobacterium carotovorum infection, Pseudomonas infection, septic peritonitis, bacterial infectious disease with sepsis, empyema, bacterial urinary tract infection, bacterial sexually transmitted disease, meningococcal infection, pasteurellosis, peritonsillar abscess, pneumonic pasteurellosis, tracheitis, Actinobacillus infectious disease, bacterial conjunctivitis, bacterial endocarditis, bacterial meningitis, Bifidobacteriales infectious disease, haemophilus infectious disease, Proteus infectious disease, pulpitis, rat-bite fever, Rickettsiosis, vibrio infectious disease, Yersinia infectious disease, bacterial myositis, noma, idiopathic severe pneumococcemia, necrotizing soft tissue infection, mycobacterial infectious disease, escherichia coli infection, gram-negative bacterial infections, gram-positive bacterial infections, spirochaetales infections, staphylococcal infection, anaerobic bacteria infectious disease, Klebsiella infectious disease, fournier gangrene, botryomycosis, bacterial hemorrhagic fever, Mycoplasmoides infection, Enterococcus infectious disease

Subtypes (17): bacillary angiomatosis, pinta disease, erysipelas, cutaneous diphtheria, cutaneous anthrax, impetigo, gonococcal keratitis, cellulitis, gas gangrene, hordeolum, bacterial exanthem, cutaneous syphilis, staphylococcal scalded skin syndrome, bullous impetigo, cutaneous tuberculosis, aquarium granuloma, sycosis barbae

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

3 approved. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Daptomycin	Approved (phase 4)
Tedizolid Phosphate	Approved (phase 4)
Tigecycline	Approved (phase 4)

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	3
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00646958	PHASE2	COMPLETED	Safety and Efficacy Study of Oxazolidinones to Treat Uncomplicated Skin Infections
NCT00719810	PHASE2	COMPLETED	Safety and Efficacy Study of a Fluoroquinolone to Treat Complicated Skin Infections
NCT03716024	PHASE2	COMPLETED	Study the Efficacy and Safety of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)
NCT01700842	Not specified	COMPLETED	Multicenter Study of Antimicrobial Resistance of Gram-positive and Gram-negative Clinical Strains to Ceftaroline and Other Antimicrobials in Russia
NCT02024867	Not specified	COMPLETED	Evaluation of 3 Versus 10 Days of Antibiotics in Skin Abscesses After Surgical Drainage

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
LINEZOLID	4	2
OMADACYCLINE	4	2
DELAFLOXACIN	4	1
TIGECYCLINE	4	1
RADEZOLID	2	1
CHEMBL4468082	0	1